MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: liver resection
MedXY News
EnglishTag

liver resection

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationcritical carebiomarkersartificial intelligencetype 1 diabetesclinical trialsHypertensiononcologyCardiologyMortalitypublic healthcardiovascular diseasediabetesAlzheimer's diseasebreast cancerepidemiology

Latest news

Tag

AI-Driven 3D Liver Modeling Enhances Prediction of Liver Resection Complexity from Preoperative CT Scans
General Surgery3D Modelingartificial intelligence

AI-Driven 3D Liver Modeling Enhances Prediction of Liver Resection Complexity from Preoperative CT Scans

By MedXY|Oct 7, 2026

An AI-based automatic 3D virtual liver modeling tool accurately predicts intraoperative liver resection complexity (LRC) from preoperative CT scans, outperforming surgeons’ assessments and potentially improving surgical planning and p

Glucagon-like Peptide-1 Receptor Agonists Versus Dipeptidyl Peptidase-4 Inhibitors Following Liver Resection for Hepatocellular Carcinoma in Type 2 Diabetes: Insights from a Target Trial Emulation Study
Clinical Updates
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
DPP‑4 inhibitors
GLP-1 receptor agonists

Glucagon-like Peptide-1 Receptor Agonists Versus Dipeptidyl Peptidase-4 Inhibitors Following Liver Resection for Hepatocellular Carcinoma in Type 2 Diabetes: Insights from a Target Trial Emulation Study

By MedXY|Jul 5, 2026

Postoperative GLP-1RA initiation after liver resection for hepatocellular carcinoma in type 2 diabetes patients is associated with improved recurrence-free and overall survival compared to DPP-4 inhibitors, indicating potential incremental

Liver Resection Post Atezo/Bev Induction Enhances Disease Control in Locally Advanced Hepatocellular Carcinoma
newsatezolizumabbevacizumab

Liver Resection Post Atezo/Bev Induction Enhances Disease Control in Locally Advanced Hepatocellular Carcinoma

By MedXY|Oct 30, 2025

Phase 3 TALENTop trial interim results show liver resection following atezolizumab plus bevacizumab induction significantly prolongs time to treatment failure in advanced HCC without extrahepatic spread.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models